Related Experiment Videos

A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors

Edward C Chao1

  • 1Division of Endocrinology and Metabolism, University of California, San Diego and VA San Diego, 3350 La Jolla Village Drive, San Diego, California 92161, USA. edward.chao@va.gov

Discovery Medicine
|March 31, 2011
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer a novel approach to managing type 2 diabetes by increasing glucose excretion. These agents show potential for lowering plasma glucose and body weight with minimal adverse effects.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) plays a key role in renal glucose reabsorption.
  • Inhibition of SGLT2 presents a novel, insulin-independent therapeutic strategy for diabetes management.
  • Genetic studies and preclinical data support the safety and efficacy of targeting SGLT2.

Purpose of the Study:

  • To review the role of SGLT2 in glucose homeostasis.
  • To evaluate the evidence for SGLT2 inhibitors in treating type 2 diabetes.
  • To discuss the potential clinical applications and advantages of SGLT2 inhibitors.

Main Methods:

  • Review of preclinical and clinical studies on SGLT2 inhibitors.
  • Analysis of data from type 2 diabetes patients.
  • Examination of genetic evidence related to SGLT2 function.

Main Results:

  • SGLT2 inhibition increases renal glucose excretion, lowering plasma glucose levels.
  • SGLT2 inhibitors have demonstrated efficacy in reducing body weight.
  • Current data suggest a favorable safety profile for SGLT2 inhibitors, with limited adverse effects.

Conclusions:

  • SGLT2 inhibitors represent a promising therapeutic class for type 2 diabetes.
  • These agents offer an insulin-independent mechanism for glycemic control.
  • SGLT2 inhibitors, such as dapagliflozin, may provide advantages over existing diabetes medications.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...